Clinical Trial Update: Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating IDEC-152 for chronic lymphocytic leukemia reported safety and preliminary efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• IDEC-152

Snippet

Sponsor: Biogen | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED